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Introduction
Multiple myeloma (MM) is an incurable accumulative disease of plasma cells characterized by dysregulation of Bcl family members 1 . These apoptosis regulatory proteins are divided into pro-and anti-apoptotic groups. The former consists of multi-domain proteins (e.g., Bak and Bax) and BH3-only proteins (e.g., Bim, Bid, Puma, Noxa, Bad, Bik, Bmf, and Hrk etc.).
The latter include multi-domain proteins e.g., Bcl-2, Bcl-xL, Mcl-1 2 . Whereas Bax/Bak are absolutely required for apoptosis, BH3-only proteins, which convert noxious stimuli into death signals 2 , consist of "activators" (e.g., Bim) and "sensitizers/derepressors" (e.g., Noxa, Bik) 2 .
Evidence implicating BH3-only proteins in anti-cancer agent-induced apoptosis 3;4 prompted the development of BH3-mimetics that bind to and inactivate anti-apoptotic Bcl proteins 5 .
One such agent, ABT-737, binds avidly to Bcl-2/Bcl-xL, but not Mcl-1 6 : consequently, relative levels of Bcl-2/Bcl-xL versus Mcl-1 determine susceptibility to this agent 7 . Mcl-1 is highly expressed in MM (e.g., in 51% patients at diagnosis and 81% at relapse), while high Mcl-1 expression correlates with poor clinical outcome 8 . Mcl-1 also plays an important role in resistance to agents such as bortezomib 9 . Recently, the novel pan-BH3-mimetic obatoclax has been developed which in addition to other anti-apoptotic proteins, antagonizes the activity of Mcl-1 in various tumors types 10;11 , including hematological malignancies such as MM.
Preclinical in vitro studies in MM demonstrated single-agent activity and additivity with other agents, but limited in vivo bioactivity when administered alone 12 .
Cyclin-dependent kinases (Cdks) regulate cell cycle progression and transcription 13 . PanCdk inhibitors such as flavopiridol (FP; alvocidib) act in part by inhibiting Cdk9, a kinase involved in RNA polymerase II (Pol II)-mediated transcription elongation 13 . Consequently, Cdk inhibitors block gene transcription and down-regulate short-lived proteins including Mcl-1, 5 promoting apoptosis 14;15 . Recently, several new-generation pan-Cdk inhibitors (e.g., CYC202, SCH727965), which also target Cdk9, have entered clinical trials 13 .
Although pan-Cdk inhibitors have been shown to potentiate ABT-737 lethality in transformed cells by down-regulating , it is unknown whether synergistic interactions would occur with pan-BH3-mimetics like obatoclax, which bind to/inactivate Mcl-1 10 . To address this question, we examined interactions between the protoyptical pan-Cdk inhibitor FP and obatoclax in human MM cells. Here we report that FP synergistically increases obatoclax lethality in diverse MM cells, including those resistant to novel agents, in the presence of stromal cell factors, and in primary CD138 + MM samples, but not in their normal counterparts.
Significantly, obatoclax/FP co-administration, in sharp contrast to obatoclax alone, displays marked in vivo activity and increases survival in multiple murine systems. From a mechanistic standpoint, the unexpected up-regulation of multiple BH3-only proteins, including BimEL, BimL, Noxa, and Bik/NBK, cooperates with down-regulation of anti-apoptotic proteins (e.g.,
Mcl-1, Bcl-xL) to play a significant functional role in lethality. Collectively, these findings provide proof of principle for a novel anti-MM strategy in which pan-Cdk inhibitors are combined with pan-BH3 mimetics, and highlight the critical importance of interplay between pro-and anti-apoptotic proteins in synergistic interactions between such agents.
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Materials and Methods
Cells and reagents
Human MM U266 and RPMI8226 cells were obtained from ATCC and maintained as before 19 . Both were authenticated (Basic STR Profiling Service, ATCC 
Procedures for in vitro studies
Animal studies
Animal studies were approved by the Virginia Commonwealth University IACUC, and performed in accordance with the U.S. Department of Agriculture and Department of Health and Human Services, and the NIH. Three mouse models were employed in this study. 
Statistical analysis
Values represent the means ± SD for at least three independent experiments performed in triplicate. The significance of differences between experimental variables was determined using the Student's t test or One-way ANOVA with Tukey-Kramer Multiple Comparisons Test. The significance of P values was < 0.05 (*), < 0.01 (**), or < 0.001 (***) wherever indicated.
Analysis of synergism was performed according to Median Dose Effect analysis using the software Calcusyn (Biosoft, Ferguson, MO). Kaplan-Meier analysis of mouse survival or hindleg paralysis was performed using IBM SPSS Statistics software.
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Results
Cdk inhibitors synergistically potentiate BH3-mimetic lethality by engaging the mitochondria-related apoptotic cascade
Co-administration (24hr) of minimally toxic concentrations of obatoclax and FP sharply reduced mitochondrial membrane potential and increased 7-AAD uptake in U266 cells (Fig 1A) , (Fig 1B) . Interactions occurred at obatoclax concentrations as low as 300nM (data not shown). Median Dose Effect analysis revealed CI values less than 1.0, indicating synergism ( Fig   1C) . Whereas individual treatment had only modest effects, combined exposure markedly increased AIF and cytochrome c cytosolic release (Fig 1D, left panels) , and caspase-3, -8, -9, and PARP cleavage (right panels). Apoptosis was confirmed by TUNEL staining (data not shown).
Concordant results were observed in other human MM lines (Fig 5C) . Similar interactions were observed when other pan-Cdk inhibitors (e.g., SCH727965) and pan-Bcl-2 antagonists (e.g., HA14-1) were employed (Suppl Fig S1A) .
Cdk inhibitor/BH3-mimetic interactions are associated with Mcl-1 and Bcl-xL downregulation
Immunoblot analysis revealed Mcl-1 down-regulation 6h after FP exposure, with recovery at 16h (Fig 2A) despite the fact that inhibition of Pol II CTD phosphorylation (serine 2) persisted (Suppl Fig S1B) , a phenomenon observed in an earlier study 14 . Obatoclax alone clearly decreased Mcl-1 levels in a dose-and time-dependent manner 21 . Notably, FP/obatoclax coadministration prevented recovery from Mcl-1 down-regulation at later intervals (e.g., 16h -48h; II CTD at 6h (Fig 2B, left panels) and 16h (Suppl Fig S1B) , indicating Cdk9/cyclin T (P-TEFb) inhibition. Moreover, in FP/obatoclax-treated cells, co-administration of the translation inhibitor CHX further reduced Mcl-1 levels (Fig 2B, middle panels) , whereas the proteasome inhibitor MG-132 failed to restore Mcl-1 expression (Fig 2B, right panels , a phenomenon largely attenuated by FP (Fig 2C and Suppl Fig S1C) .
Effects on Bcl-xL, which cooperates with Mcl-1 to tether and inactivate Bak 22 , were then examined. Exposure of U266 cells to FP +/-obatoclax reduced Bcl-xL levels in a timedependent manner (Suppl Fig S2A) , while CHX failed to further down-regulate Bcl-xL (Suppl Fig S2B) . In contrast, Bcl-2 protein levels remained unchanged with all treatments (Suppl Fig   S2C, left panels) . Analogous results were obtained in RPMI8226 cells (Suppl Fig S2C, Ectopic expression of Mcl-1 partially but significantly attenuated FP/obatoclax lethality at 24h (Fig 2D and Suppl Fig S2D) . However, protection was not statistically significant at 48h (Fig 2D) . In contrast, cells overexpressing Mcl-1 were substantially resistant to bortezomib at both 24h and 48h (Fig 2D) , consistent with previous reports 9 . Bcl-xL over-expression partially but significantly protected cells from FP/obatoclax lethality at both 24h and 48h (Suppl Fig   S2E) . Together, these findings suggest that Mcl-1 and Bcl-xL down-regulation plays a significant but limited functional role in FP/obatoclax lethality. Fig 3A) , Bik/NBK (Suppl Fig S3A) , and Noxa (Suppl Fig   S3B) .
Consistent with results in other tumor cell types 21 , obatoclax played a major role in Noxa up-regulation. Time course analysis of U266 cells revealed that obatoclax alone sharply increased Noxa levels as early as 6h after exposure, but this effect was no longer apparent after 16h (data not shown). Notably, obatoclax-induced Noxa up-regulation was sustained for longer intervals (e.g., at least 24h) in the presence of FP (Suppl Fig S3B, upper panels) . Similar events occurred in RPMI8226 cells (Suppl Fig S3B, lower panels) . Importantly, Noxa shRNA dramatically blocked apoptosis induced by either bortezomib 23 or FP/obatoclax (Suppl Fig   S3C) , arguing that up-regulation of the BH3-only protein Noxa plays a significant functional role in FP/obatoclax lethality..
Up-regulation of Bim at the transcriptional level plays a significant functional role in Cdk inhibitor/BH3-mimetic interactions
The functional significance of up-regulation of the direct activator Bim 24 was then examined. FP induced Bim expression (EL and L isoforms), with or without obatoclax, in U266 (Fig 3A, left panels) and RPMI8226 cells (right panels). Immunoblot analysis confirmed increased expression of both Bim isoforms after FP treatment alone (Fig 3B, left panels 
12
after treatment. In contrast, obatoclax alone did not up-regulate Bim (data not shown). FPinduced Bim induction was largely blocked by CHX (Fig 3C) , suggesting a requirement for de novo protein synthesis. Moreover, qPCR demonstrated significant increases in Bim mRNA levels at 3h, 6h, and 16h after FP treatment with or without obatoclax in both U266 and RPMI8226 cells (Fig 3D and Suppl Fig S3D) , arguing that Bim up-regulation by FP occurs at the transcriptional level.
Co-immunoprecipitation was performed to examine interactions between Bim and antiapoptotic Bcl proteins. Whereas bortezomib increased BimEL rather than BimL bound to Bcl-2 and particularly to Bcl-xL, FP alone clearly increased Bim (EL and L) binding to Bcl-2 and BclxL ( Fig 4A) . The latter events were markedly attenuated by obatoclax. Interestingly, FP or obatoclax alone modestly diminished BimEL bound to Mcl-1, an effect only slightly enhanced with the combination (Fig 4A) . In FP-treated cells, unleashing of Bim from both Bcl-2 and BclxL by obatoclax was associated with conformational activation of Bax and to a lesser extent Bak (Fig 4B, left panels) , as well as Bax mitochondrial translocation (right panels), triggering mitochondrial outer membrane permeabilization (MOMP), caspase activation, and pronounced apoptosis (Fig 1D) . Moreover, transient transfection of a construct encoding Bax shRNA significantly diminished FP/obatoclax lethality (Suppl Fig S3E) .
To define the functional role of Bim up-regulation, U266 cells were stably transfected with a constructs encoding shRNA targeting Bim (shBim). In these cells, both BimEL and BimL were substantially knocked down, compared to (shNC) scrambled sequence negative controls (Fig 4C, left panel) . Notably, shBim essentially abrogated FP/obatoclax-mediated lethality (Fig caspase activation, and PARP cleavage (Fig 4D) induced by FP/obatoclax. However, coexposure to FP/obatoclax induced nearly equivalent Mcl-1 down-regulation in both shNC and shBim cells (Fig 4D) . Analogous results were obtained when another Bim shRNA was employed (Suppl Fig S3C) . Together, these findings raise the possibility that unleashing of up-regulated Bim from anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL, Mcl-1) by obatoclax contributes to synergistic interactions. They also argue that in the setting of down-regulation of anti-apoptotic proteins, up-regulation of BH3-only proteins such as Bim plays a critical functional role in lethality.
The Cdk inhibitor/BH3-mimetic regimen is active against MM cells displaying conventional or novel forms of drug resistance, as well as primary MM cells
In addition to drug resistance due to Bcl family dysregulation, microenvironmental factors also confer resistance in MM 26 . To address these issues, U266 cells were cultured in the presence of HS-5 cells (a human BM stromal cell line) 27 , HS-5-conditional medium (CM), or both. Whereas CM slightly reduced Bim levels, co-culture with HS-5 markedly down-regulated Bim (Fig 5A) . Notably, HS-5 plus CM essentially abolished Bim expression, raising the possibility that Bim down-regulation represents a mechanism underlying stromal cell-mediated drug resistance 28 . Importantly, neither HS-5 ± CM prevented FP/obatoclax lethality (P > 0.05, , obatoclax (3mg/kg) alone had no effect on tumor growth, manifested by luciferase activity (Fig 6A, left panels) . However, whereas FP (5mg/kg) alone exerted modest but discernible effects, combined treatment substantially suppressed tumor growth. The size of tumors excised from mice confirmed pronounced tumor growth suppression with combined treatment (Fig 6A, right panels) .
Moreover, tumor size measurements yielded concordant results (P = 0.0002, Fig 6B) .
Interestingly, immunoblot analysis of tumor tissues revealed that FP/obatoclax co-administration down-regulated Mcl-1 and up-regulated Bim (particularly the L isoform) and Noxa, accompanied by caspase-3 activation and PARP cleavage (Fig 6C) , consistent with in vitro observations.
To determine whether BH3-only protein up-regulation (e.g., Bim) plays a significant functional role in FP/obatoclax lethality in vivo, NOD/SCID-gamma mice were inoculated s.c.
with U266 cells stably transfected with shBim or shNC respectively (Fig 4C) in each flank, after which FP (3mg/kg, i.p.) ± obatoclax (3mg/kg, i.p.) was administered. FP/obatoclax coadministration markedly suppressed growth of shNC tumors (Fig 6D, right flank) , analogous to results observed in the previously described flank model (Fig 6A-C) . Notably, whereas a slight reduction in tumor size was observed in the obatoclax group, no obvious growth suppression was observed by FP alone or with obatoclax in shBim tumors (Fig 6D, left flank) , demonstrating an important functional role for Bim in FP/obatoclax lethality in vivo.
The BM microenvironment plays a critical role in survival, growth, and drug-resistance of MM cells 26 . CAN-12-1118 this orthotopic murine model, NOD/SCID-gamma mice were injected with U266 cells stably transfected with a luciferase gene, after which homing and growth of tumor cells were dynamically monitored by imaging luciferase activity. Notably, U266 cells homed to BM and then formed lesions at skeletal sites (Fig 7A) , without detectable lesions in other organs, findings confirmed by IHC staining for human CD138 (data not shown). At later intervals (9 -13 weeks after cell injection), inoculated mice displayed hind-leg paralysis (Fig 7B, right panels) , a classic indicator of bone disease. After luciferase signals were visible, FP (5mg/kg, i.p.) ± obatoclax (3mg/kg, i.p.) were administered daily for five days, followed by FP (3mg/kg) ± obatoclax (3mg/kg) twice every three days. Tumor growth was monitored every two days. As shown in Fig   7A , combined treatment substantially reduced tumor burden compared to agents administered individually. Kaplan-Meier hazard analysis demonstrated that whereas obatoclax alone clearly delayed the appearance of hind-leg paralysis, FP alone had only minimal effects (Fig 7B) .
Notably, hind-leg paralysis did not appear in any mice in the FP/obatoclax group throughout the entire four month observation period (P = 0.0268, Fig 7B, Suppl Video) . Moreover, KaplanMeier survival analysis revealed more prolonged survival of mice receiving combined treatment compared to mice treated with FP or obatoclax alone (P = 0.0161, Fig 7C) . Finally, significant neurologic toxicity (e.g., onset of agitation and hyperactivity), which has been noted immediately after a rapid i.v. injection of obatoclax (4mg/kg) 12 , was not observed in mice after either i.m. or i.p. obatoclax (3mg/kg) alone or in combination with FP, similar to results with i.v. injection of 2mg/kg obatoclax in mice bearing solid tumors 11 . Moreover, there was no significant loss of body weight (Fig 7D) or other signs of toxicity observed after FP and obatoclax administrated alone or in combination in these murine systems. Together, these findings argue that an anti-MM regimen combining a pan-Cdk inhibitor with a pan-BH3-mimetic is active in vivo, and suggest 
Discussion
Tumor cells are commonly characterized by over-expression of anti-apoptotic Bcl proteins (e.g., Bcl-2, Bcl-xL, or Mcl-1), which contributes to drug-resistance by disabling the death machinery 30;31 . Transformed cells also frequently express pro-apoptotic Bcl proteins including multi-domain (e.g., Bax and Bak) and some, if not all, BH3-only proteins such as 
